Association of serum docosahexaenoic acid with cerebral amyloidosis

JAMA Neurology

Volumn 73, Issue 10, 2016, Pages 1208-1216

  Yassine, Hussein N ^a   Feng, Qingru ^a   Azizkhanian, Ida ^a   Rawat, Varun ^a   Castor, Katherine ^b   Fonteh, Alfred N ^b   Harrington, Michael G ^b   Zheng, Ling ^a   Reed, Bruce R ^c   DeCarli, Charles ^c   Jagust, William J ^d   Chui, Helena C ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b HUNTINGTON MEDICAL RESEARCH INSTITUTES   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; APOLIPOPROTEIN E; DOCOSAHEXAENOIC ACID; PITTSBURGH COMPOUND B; 2-(4'-(METHYLAMINO)PHENYL)-6-HYDROXYBENZOTHIAZOLE; AMYLOID BETA PROTEIN; ANILINE DERIVATIVE; THIAZOLE DERIVATIVE;

AGED; ALZHEIMER DISEASE; AMYLOIDOSIS; ARTICLE; BRAIN SIZE; CEREBRAL AMYLOIDOSIS; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FATTY ACID BLOOD LEVEL; FATTY ACID METABOLISM; FEMALE; GENOTYPE; HUMAN; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGICAL TEST; NONVERBAL MEMORY TEST; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; BLOOD; BRAIN DISEASE; DIAGNOSTIC IMAGING; METABOLISM; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOIDOSIS; ANILINE COMPOUNDS; BRAIN DISEASES; CROSS-SECTIONAL STUDIES; DOCOSAHEXAENOIC ACIDS; FEMALE; HUMANS; MALE; POSITRON-EMISSION TOMOGRAPHY; THIAZOLES;

EID: 84998706975     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2016.1924     Document Type: Article

References (53)

1. Qiu C, Kivipelto M, von Strauss E. Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci. 2009;11(2):111-128.
2. Gu Y, Brickman AM, Stern Y, et al. Mediterranean diet and brain structure in a multiethnic elderly cohort. Neurology. 2015;85(20):1744-1751.
3. Tully AM, Roche HM, Doyle R, et al. Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer's disease: a case-control study. Br J Nutr. 2003;89(4):483-489.
4. Conquer JA, Tierney MC, Zecevic J, Bettger WJ, Fisher RH. Fatty acid analysis of blood plasma of patients with Alzheimer's disease, other types of dementia, and cognitive impairment. Lipids. 2000; 35(12):1305-1312.
5. Cunnane SC, Schneider JA, Tangney C, et al. Plasma and brain fatty acid profiles in mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis. 2012;29(3):691-697.
6. Lim GP, Calon F, Morihara T, et al. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burdenin anaged Alzheimer mouse model.JNeurosci. 2005;25(12):3032-3040.
7. Calon F, Lim GP, Yang F, et al. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron. 2004; 43(5):633-645.
8. Green KN, Martinez-Coria H, Khashwji H, et al. Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-β and tau pathology viaa mechanism involving presenilin 1 levels. J Neurosci. 2007;27(16): 4385-4395.
9. Yehuda S, Rabinovitz S, Mostofsky DI. Essential fatty acids are mediators of brain biochemistry and cognitive functions. J Neurosci Res. 1999;56(6): 565-570.
10. Pottala JV, Yaffe K, Robinson JG, Espeland MA, Wallace R, Harris WS. Higher RBC EPA + DHA corresponds with larger total brain and hippocampal volumes: WHIMS-MRI study. Neurology. 2014;82 (5):435-442.
11. Daiello LA, Gongvatana A, Dunsiger S, Cohen RA, Ott BR; Alzheimer's Disease Neuroimaging Initiative. Association of fish oil supplement use with preservation of brain volume and cognitive function. Alzheimers Dement. 2015;11(2):226-235.
12. Oksman M, Iivonen H, Hogyes E, et al. Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on beta-amyloid accumulation in APP/PS1 transgenic mice. Neurobiol Dis. 2006;23(3):563-572.
13. Grimm MO, Kuchenbecker J, Grösgen S, et al. Docosahexaenoic acid reduces amyloid β production via multiple pleiotropic mechanisms. J Biol Chem. 2011;286(16):14028-14039.
14. Hjorth E, Zhu M, Toro VC, et al. Omega-3 fatty acids enhance phagocytosis of Alzheimer's disease-related amyloid-β42 by human microglia and decrease inflammatory markers. J Alzheimers Dis. 2013;35(4):697-713.
15. Reed BR, Mungas DM, Kramer JH, et al. Profiles of neuropsychological impairment in autopsy-defined Alzheimer's disease and cerebrovascular disease. Brain. 2007;130(pt 3):731-739.
16. Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents.JMed Chem. 2003;46(13): 2740-2754.
17. Reed B, Villeneuve S, Mack W, DeCarli C, Chui HC, Jagust W. Associationsbetween serum cholesterol levels and cerebral amyloidosis. JAMA Neurol. 2014;71(2):195-200.
18. Fonteh AN, Cipolla M, Chiang J, Arakaki X, Harrington MG. Human cerebrospinal fluid fatty acid levels differ between supernatant fluid and brain-derived nanoparticle fractions, and are altered in Alzheimer's disease. PLoS One. 2014;9 (6):e100519.
19. Baylin A, Kim MK, Donovan-Palmer A, et al. Fasting whole blood as a biomarker of essential fatty acid intake in epidemiologic studies: comparison with adipose tissue and plasma. Am J Epidemiol. 2005;162(4):373-381.
20. Sun Q, Ma J, Campos H, et al. Blood concentrations of individual long-chain n-3 fatty acids and risk of nonfatal myocardial infarction. Am J Clin Nutr. 2008;88(1):216-223.
21. Villeneuve S, Reed BR, Madison CM, et al. Vascular risk and Aβ interact to reduce cortical thickness in AD vulnerable brain regions. Neurology. 2014;83(1):40-47.
22. Kontush A, Lhomme M, Chapman MJ. Unraveling the complexities of the HDL lipidome. J Lipid Res. 2013;54(11):2950-2963.
23. Witte AV, Kerti L, Hermannstädter HM, et al. Long-chain omega-3 fatty acids improve brain function and structure in older adults. Cereb Cortex. 2014;24(11):3059-3068.
24. Jernerén F, Elshorbagy AK, Oulhaj A, Smith SM, Refsum H, Smith AD. Brain atrophy in cognitively impaired elderly: the importance of long-chain ω-3 fatty acids and B vitamin status in a randomized controlled trial. Am J Clin Nutr. 2015;102(1):215-221.
25. Andersen OM, Willnow TE. Lipoprotein receptors in Alzheimer's disease. Trends Neurosci. 2006;29(12):687-694.
26. Poirier J, Baccichet A, Dea D, Gauthier S. Cholesterol synthesis and lipoprotein reuptake during synaptic remodelling in hippocampus in adult rats. Neuroscience. 1993;55(1):81-90.
27. Vandal M, Alata W, Tremblay C, et al. Reduction in DHA transport to the brain of mice expressing human APOE4 compared to APOE2. JNeurochem. 2014;129(3):516-526.
28. Quinn JF, Raman R, Thomas RG, et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA. 2010;304(17):1903-1911.
29. Freund-Levi Y, Eriksdotter-Jönhagen M, Cederholm T, et al. ω-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol. 2006;63(10):1402-1408.
30. Vellas B, Carrie I, Gillette-Guyonnet S, et al. MAPT study: a multidomain approach for preventing Alzheimer's disease: design and baseline data. J Prev Alzheimers Dis. 2014;1(1):13-22.
31. Yurko-Mauro K, McCarthy D, Rom D, et al; MIDAS Investigators. Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimers Dement. 2010;6(6): 456-464.
32. Johnson EJ, McDonald K, Caldarella SM, Chung HY, Troen AM, Snodderly DM. Cognitive findings of an exploratory trial of docosahexaenoic acid and lutein supplementation in older women. Nutr Neurosci. 2008;11(2):75-83.
33. Boehm-Cagan A, Michaelson DM. Reversal of apoE4-driven brain pathology and behavioral deficits by bexarotene. J Neurosci. 2014;34(21): 7293-7301.
34. Kariv-Inbal Z, Yacobson S, Berkecz R, et al. The isoform-specific pathological effects of apoE4 in vivo are prevented by a fish oil (DHA) diet and are modified by cholesterol. J Alzheimers Dis. 2012;28 (3):667-683.
35. Huang TL, Zandi PP, Tucker KL, et al. Benefits of fatty fish on dementia risk are stronger for those without APOE epsilon4. Neurology. 2005;65(9): 1409-1414.
36. Barberger-Gateau P, Raffaitin C, Letenneur L, et al. Dietary patterns and risk of dementia: the Three-City cohort study. Neurology. 2007;69(20): 1921-1930.
37. Whalley LJ, Deary IJ, Starr JM, et al. n-3 Fatty acid erythrocyte membrane content, APOE varepsilon4, and cognitive variation: an observational follow-up study in late adulthood. Am J Clin Nutr. 2008;87(2):449-454.
38. van de Rest O, Geleijnse JM, Kok FJ, et al. Effect of fish oil on cognitive performance in older subjects: a randomized, controlled trial. Neurology. 2008;71(6):430-438.
39. Morris MC, Evans DA, Bienias JL, et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol. 2003;60 (7):940-946.
40. Samieri C, Féart C, Proust-Lima C, et al. ω-3 fatty acids and cognitive decline: modulation by ApoEϵ4 allele and depression. Neurobiol Aging. 2011;32(12):2317.e13-2317.e22.
41. Stonehouse W, Conlon CA, Podd J, et al. DHA supplementation improved both memory and reaction time in healthy young adults: a randomized controlled trial. Am J Clin Nutr. 2013;97(5):1134-1143.
42. Morris MC, Brockman J, Schneider JA, et al. Association of seafood consumption, brain mercury level, and APOE ϵ4 status with brain neuropathology in older adults. JAMA. 2016;315(5):489-497.
43. Beydoun MA, Kaufman JS, Satia JA, Rosamond W, Folsom AR. Plasma n-3 fatty acids and the risk of cognitive decline in older adults: the Atherosclerosis Risk in Communities Study. Am J Clin Nutr. 2007;85 (4):1103-1111.
44. Kröger E, Verreault R, Carmichael PH, et al. Omega-3 fatty acids and risk of dementia: the Canadian Study of Health and Aging. Am J Clin Nutr. 2009;90(1):184-192.
45. Rönnemaa E, Zethelius B, Vessby B, Lannfelt L, Byberg L, Kilander L. Serum fatty-acid composition and the risk of Alzheimer's disease: a longitudinal population-based study. Eur J Clin Nutr. 2012;66(8): 885-890.
46. Chiu C-C, Su K-P, Cheng T-C, et al. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32(6):1538-1544.
47. Lee LK, Shahar S, Chin A-V, Yusoff NAM. Docosahexaenoic acid-concentrated fish oil supplementation in subjects with mild cognitive impairment (MCI):a 12-month randomised, double-blind, placebo-controlled trial. Psychopharmacology (Berl). 2013;225(3):605-612.
48. Salloway S, Sperling R, Fox NC, et al; Bapineuzumab 301 and 302 Clinical Trial Investigators. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med. 2014;370(4):322-333.
49. Monsell SE, Kukull WA, Roher AE, et al. Characterizing apolipoprotein E ϵ4 carriers and noncarriers with the clinical diagnosis of mild to moderate Alzheimer dementia and minimal β-amyloid peptide plaques. JAMA Neurol. 2015;72 (10):1124-1131.
50. Fleisher AS, Chen K, Liu X, et al. Apolipoprotein E ϵ4 and age effects on florbetapir positron emission tomographyin healthy aging and Alzheimer disease. Neurobiol Aging. 2013;34(1):1-12.
51. Marchant NL, Reed BR, DeCarli CS, et al. Cerebrovascular disease, β-amyloid, and cognition in aging. Neurobiol Aging. 2012;33(5):1006.e25-1006.e36.
52. Calon F. Omega-3 polyunsaturated fatty acids in Alzheimer's disease: key questions and partial answers. Curr Alzheimer Res. 2011;8(5):470-478.
53. Yassine HN, Rawat V, Mack WJ, et al. The effect ofAPOE genotype onthe delivery of DHA to cerebrospinal fluid in Alzheimer's disease. Alzheimers Res Ther. 2016;8:25.